Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

1672803

USP

Transplatin

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

trans-Platin(II)diammindichlorid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Lineare Formel:
Pt(NH3)2Cl2
CAS-Nummer:
14913-33-8
Molekulargewicht:
300.05
MDL-Nummer:
MFCD00011623
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329751363
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

cisplatin

Hersteller/Markenname

USP

mp (Schmelzpunkt)

340 °C (dec.) (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChIKey

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

C2210000

Cisplatin, European Pharmacopoeia (EP) Reference Standard

Y0001019

Cisplatin Unreinheit B, European Pharmacopoeia (EP) Reference Standard

Y0001018

Cisplatin Unreinheit A, European Pharmacopoeia (EP) Reference Standard

1551300

Kaliumtrichloramminplatinat, United States Pharmacopeia (USP) Reference Standard

1134357

Cisplatin, United States Pharmacopeia (USP) Reference Standard

PHR1624

cis-Diamminplatin(II)-dichlorid, Pharmaceutical Secondary Standard; Certified Reference Material

BP809

Cisplatin, British Pharmacopoeia (BP) Reference Standard

BP510

Kaliumtrichloramminplatinat, British Pharmacopoeia (BP) Reference Standard

BP544

Transplatin, British Pharmacopoeia (BP) Reference Standard

Piktogramme

Health hazardCorrosion
GHS08,GHS05

Signalwort

Danger

Gefahreneinstufungen

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

Lagerklassenschlüssel

13 - Non Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Yuniardini S Wimardhani et al.
Journal of oral science, 56(2), 119-126 (2014-06-17)
Chitosan, a multipurpose biomaterial, has been shown to exert effects against several types of cancer including oral cancer. However, the mechanisms underlying the anticancer activities of chitosan on oral squamous cell carcinoma (SCC) cells remain largely unknown. The present study
Michelle X Liu et al.
Oncotarget, 5(4), 944-958 (2014-03-25)
Epithelial ovarian cancer is a highly lethal and aggressive gynecological malignancy. The high mortality rate is due in part to the fact that many advanced cancer patients become refractory to current chemotherapeutic agents, leading to tumor recurrence and death. However
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
Wei Qian et al.
Oncotarget, 5(12), 4180-4194 (2014-06-24)
Overcoming platinum drug resistance represents a major clinical challenge in cancer treatment. We discovered a novel drug combination using cisplatin and a class of thioquinazolinone derivatives including mdivi-1 (mitochondrial division inhibitor-1), that induces synergistic apoptosis in platinum resistant tumor cells
James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.